Stocks News

LAST PRICE
27.3400
TODAY'S CHANGE (%)
Trending Up0.1000 (0.3671%)

Bid / Lots
25.0500/ 18
Ask / Lots
29.9500/ 10
Open / Previous Close
27.1200 / 27.2400
Day Range
Low 26.7500
High 27.7500
52 Week Range
Low 4.9600
High 28.4200
Volume
806,669
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 6, 2024
- DJ Nurix Therapeutics Price Target Maintained With a $29.00/Share by Needham, from 6:19AM ET on Wednesday Nov 06, 2024 by Dow Jones
  6:19AM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: NRIX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 06, 2024 06:19 ET (11:19 GMT)
Nov 5, 2024
- Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting, from 9:01AM ET on Tuesday Nov 05, 2024 by Dow Jones
  9:01AM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: NRIX
  
  Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
  
  SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that data will be presented from its two Bruton's tyrosine kinase (BTK) degrader programs, NX-5948 and NX-2127, in two oral presentations and one poster at the 66th American Society of Hematology Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, CA.
Oct 31, 2024
- Nurix Therapeutics to Participate in Upcoming Investor Conferences, from 7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: NRIX
  
  Nurix Therapeutics to Participate in Upcoming Investor Conferences
  
  SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in the following conferences in November:
Oct 24, 2024
- UBS Initiates Nurix Therapeutics With Buy Rating, $35 Price Target, from 11:13AM ET on Thursday Oct 24, 2024 by MT Newswires
  11:13AM ET on Thursday Oct 24, 2024 by MT Newswires
  Companies Mentioned: NRIX
  11:13 AM EDT, 10/24/2024 (MT Newswires) -- Nurix Therapeutics (NRIX) has an average outperform rating and price target range of $16 to $41, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from...
- DJ Nurix Therapeutics Initiated at Buy by UBS, from 7:55AM ET on Thursday Oct 24, 2024 by Dow Jones
  7:55AM ET on Thursday Oct 24, 2024 by Dow Jones
  Companies Mentioned: NRIX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 24, 2024 07:55 ET (11:55 GMT)

Yesterday
- Disc Medicine Gets $200 Million Loan From Hercules Capital, from 10:41AM ET on Friday Nov 08, 2024 by MT Newswires
  10:41AM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: HTGC, IRON
- Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc., from 8:30AM ET on Friday Nov 08, 2024 by Dow Jones
  8:30AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: HTGC, IRON
- Press Release: Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc., from 8:30AM ET on Friday Nov 08, 2024 by Dow Jones
  8:30AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: HTGC, IRON
Nov 7, 2024
- DJ Recursion Pharmaceuticals Price Target Maintained With a $11.00/Share by Needham, from 7:36AM ET on Thursday Nov 07, 2024 by Dow Jones
  7:36AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: RXRX
Nov 6, 2024
- -- Earnings Flash (RXRX) RECURSION PHARMACEUTICALS Reports Q3 Revenue $26.1M, from 4:39PM ET on Wednesday Nov 06, 2024 by MT Newswires
  4:39PM ET on Wednesday Nov 06, 2024 by MT Newswires
  Companies Mentioned: RXRX
- Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024, from 4:30PM ET on Wednesday Nov 06, 2024 by Dow Jones
  4:30PM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: TARS
- Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results, from 4:15PM ET on Wednesday Nov 06, 2024 by Dow Jones
  4:15PM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: RXRX
- Press Release: Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results, from 4:15PM ET on Wednesday Nov 06, 2024 by Dow Jones
  4:15PM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: RXRX
Nov 5, 2024
- DJ Disc Medicine Is Maintained at Sector Outperform by Scotiabank, from 6:59PM ET on Tuesday Nov 05, 2024 by Dow Jones
  6:59PM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: IRON
- DJ Disc Medicine Price Target Maintained With a $70.00/Share by HC Wainwright & Co., from 9:45AM ET on Tuesday Nov 05, 2024 by Dow Jones
  9:45AM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: IRON

Nurix Therapeutics Inc
NASDAQ:NRIXUnited States

Search Criteria

Nov 6, 2024

DJ Nurix Therapeutics Price Target Maintained With a $29.00/Share by Needham, from 6:19AM ET on Wednesday Nov 06, 2024 by Dow Jones

Nov 5, 2024

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting, from 9:01AM ET on Tuesday Nov 05, 2024 by Dow Jones

Oct 31, 2024

Nurix Therapeutics to Participate in Upcoming Investor Conferences, from 7:00AM ET on Thursday Oct 31, 2024 by Dow Jones

Oct 24, 2024

UBS Initiates Nurix Therapeutics With Buy Rating, $35 Price Target, from 11:13AM ET on Thursday Oct 24, 2024 by MT Newswires

DJ Nurix Therapeutics Initiated at Buy by UBS, from 7:55AM ET on Thursday Oct 24, 2024 by Dow Jones

Peers Headlines

Yesterday

Disc Medicine Gets $200 Million Loan From Hercules Capital, from 10:41AM ET on Friday Nov 08, 2024 by MT Newswires

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc., from 8:30AM ET on Friday Nov 08, 2024 by Dow Jones

Press Release: Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc., from 8:30AM ET on Friday Nov 08, 2024 by Dow Jones

Nov 7, 2024

DJ Recursion Pharmaceuticals Price Target Maintained With a $11.00/Share by Needham, from 7:36AM ET on Thursday Nov 07, 2024 by Dow Jones

Nov 6, 2024

-- Earnings Flash (RXRX) RECURSION PHARMACEUTICALS Reports Q3 Revenue $26.1M, from 4:39PM ET on Wednesday Nov 06, 2024 by MT Newswires

Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024, from 4:30PM ET on Wednesday Nov 06, 2024 by Dow Jones

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results, from 4:15PM ET on Wednesday Nov 06, 2024 by Dow Jones

Press Release: Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results, from 4:15PM ET on Wednesday Nov 06, 2024 by Dow Jones

Nov 5, 2024

DJ Disc Medicine Is Maintained at Sector Outperform by Scotiabank, from 6:59PM ET on Tuesday Nov 05, 2024 by Dow Jones

DJ Disc Medicine Price Target Maintained With a $70.00/Share by HC Wainwright & Co., from 9:45AM ET on Tuesday Nov 05, 2024 by Dow Jones